Sanofi’s Strategic Acquisition of Blueprint Medicines: A Boost to Rare Disease Portfolio and Long-term Growth

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating on June 3.

David Risinger has given his Buy rating due to a combination of factors surrounding Sanofi’s strategic acquisition of Blueprint Medicines (BPMC). The $9.1 billion acquisition is set to enhance Sanofi’s rare disease portfolio, particularly through BPMC’s lead asset, Ayvakit, which is the only approved treatment for systemic mastocytosis. Sanofi management is optimistic about increasing Ayvakit’s market penetration and leveraging its expertise in rare diseases to identify and treat more patients.
Furthermore, the acquisition aligns with Sanofi’s strategy of executing bolt-on mergers and acquisitions, which is expected to be accretive to business operating income and earnings per share after 2026. The transaction also includes a contingent value right tied to the development of BLU-808, a promising KIT inhibitor. This acquisition is seen as a validation of the anticipated increase in large-cap biopharma M&A activity, supporting a positive outlook for Sanofi’s long-term growth.

According to TipRanks, Risinger is a 5-star analyst with an average return of 8.3% and a 52.15% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Sanofi.

In another report released on June 3, UBS also maintained a Buy rating on the stock with a €115.00 price target.